

PRESS RELEASE



CytoTools

CytoTools AG achieves breakthrough in treating diabetic foot with successful clinical Phase III study

- Final study phase in India confirms excellent previous results for wound healing therapy DermaPro® with 91 % cure rate
- Marketing authorization planned for 2014 – initial orders for substance already expected this year, and consequently sales revenue for CytoTools

Darmstadt, August 19, 2013 – CytoTools AG, a technology holding company with investments in the pharmaceutical and medical product area, reports a breakthrough in the treatment of diabetic foot: its subsidiary DermaTools Biotech GmbH has concluded its clinical Phase III trials in India with a 91 % cure rate. No side-effects or intolerances arose in any of the 310 patients treated. Complete wound closure has now been launched as the primary target parameter due to regulatory requirements. Here, too, the considerable superiority of DermaPro® is evident. Complete healing was achieved in the case of 71 % of the substance group in a treatment period of a maximum of six weeks, compared with 56 % in the standard therapy group by the end of the treatment period (ten weeks). "This shows that DermaPro® works significantly better in closing diabetic foot ulcerations than the active control. DermaPro® is statistically significantly superior to the standard therapy," is how Dr. Mukund Zarapkar, clinical head of the Indian study, appraised this major success.

This entirely new interaction represents an enormous improvement in treatment options for the diabetic foot indication that was tested in the Indian study of licensing partner Centaur Pharmaceuticals: "A previous standard therapy to treat these seriously chronic wounds is damp wound dressings that exhibit significantly lower healing rates. To date, no therapy form on the market has proved persuasive in controlled studies on these most severe chronic wounds. Following positive feedback from various doctors, we are very confident that treatment with DermaPro® – after corresponding approval – can become established as the new standard in the medium term," commented Dr. Dirk Kaiser, Managing Director at DermaTools Biotech GmbH. The company is pushing vigorously head with preparations for approval on the world's largest diabetes market. Its Indian partner Centaur will present detailed results of the study at the 12th Diabetic Foot Conference in Jaipur (early September) to a broad audience of specialists. The registration dossier will then be submitted to the Indian regulators.

The market launch that is planned for 2014 could already generate sales revenue growth at CytoTools AG during the course of this financial year. "We here in Germany will be fully responsible for producing and bottling the substance. The first orders and deliveries to Centaur are anticipated before the end of this year so that corresponding volumes are in stock for the market launch," is how Dr. Mark-Andre Freyberg explained the cooperation with Centaur.

Besides the successes in India, European Phase III clinical trials DermaPro® are also progressing to schedule. A further Phase IIb study for the *ulcus cruris* ("venous ulcer") indication is also to be

PRESS RELEASE



CytoTools

launched before the end of this year so that the preparation can be made accessible to an even broader patient population in the longer term.

This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: around 58% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt, Germany
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden, Germany
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de